Barcelona researchers come up with method to improve colon cancer screening
IDIBAPS research institute develops project to provide better diagnosis of tumors, detect polyps and avoid unnecessary colonoscopies
IDIBAPS research institute develops project to provide better diagnosis of tumors, detect polyps and avoid unnecessary colonoscopies
The IDIBAPS research group found molecular differences between old young and old patients
Half belong to University of Barcelona or Hospital Clínic-Idibaps
European Research Council backs project focused on Chronic Lymphocytic Leukemia
A new computational method allows the detection, within just a few hours, of the genetic alterations responsible for the formation and progression of cancer tumours. This new method manages to accurately identify almost all types of genetic changes of cancer cells in a simple, quick and precise way. It is also able to identify large-scale chromosome rearrangements, which had been difficult to be detect until this breakthrough. The new method, called SMUFIN, has been developed by the Barcelona Supercomputing Centre and the ICREA (Catalan Institution of Research and Advanced Studies), in collaboration with research groups from Barcelona, Oviedo and Heidelberg. This progress has been published by the prestigious journal 'Nature Biotechnology' and represents a significant step forward towards the personalised treatment of cancer and other illnesses.
Researchers from the University of Barcelona (UB) and the Catalan capital’s CELLEX Biomedical Research Centre (IDIBAPS-UB) have found the essential role played by cholesterol in cell mobility and tissue invasion, which also means its role in cancer propagation. In fact, this research, led by Professor Carles Enrich, is a key study for better understanding of cancer metastasis – the process in which cancer cells invade healthy tissues – and progresses the discussion on the relationship between cholesterol levels and cancer incidence. The paper is published in open access ‘Cell Reports’. In short they found that the so-called “bad” cholesterol (LDL cells) promotes cell mobility while “good” cholesterol (HDL cells) avoids cell propagation. The study opens new therapeutic paths to blocking cancer metastasis.
An international study with the participation of the Hospital Clínic IDIBAPS, which is a leading research centre at a world level on AIDS/HIV and other common diseases, has proved that an anti-retroviral treatment carried out just after the infection delays the damage to the patient’s immune system and reduces the risk of transmission. The results of clinical tests on 366 infected individuals confirmed that the sooner and longer an initial anti-retroviral treatment is applied, the later the life-long treatments have to start. However, despite the results, researchers insist that is still too soon to change the current AIDS/HIV treatment protocols.
The IDIBAPS has opened a new research centre of more than 5,000 m2, where more than 200 researchers split into 23 different research groups will be working. It will focus its work on oncology, neurosciences and cell therapies along with infectious, respiratory, cardiovascular and renal diseases. The new centre has been possible thanks to a donation by the private foundation CELLEX, sponsored by Pere Mir. The new centre is located within the University of Barcelona’s Faculty of Medicine, which is integrated into the prestigious Hospital Clínic. The centre consolidates Catalonia, and in particular Barcelona, as one of Europe’s main biomedical poles.